Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMD


Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.